DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Sunday morning. The firm issued a hold rating on the stock.

Separately, HC Wainwright dropped their price objective on shares of DBV Technologies from $20.00 to $10.00 and set a buy rating on the stock in a research note on Wednesday, May 8th.

DBV Technologies Price Performance

NASDAQ DBVT opened at $0.97 on Friday. DBV Technologies has a 52 week low of $0.84 and a 52 week high of $4.42. The stock has a market capitalization of $93.60 million, a PE ratio of -1.15 and a beta of 0.69. The firm has a 50 day moving average of $1.16 and a two-hundred day moving average of $1.50.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The business had revenue of $1.41 million during the quarter, compared to the consensus estimate of $3.20 million. On average, equities research analysts expect that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.